Outcome of ABO‐incompatible kidney transplantation using a modified desensitization protocol without plasmapheresis

Authors:

Abstract
Objectives: Several controversies regarding desensitization strategies for successful ABO‐incompatible (ABOi) kidney transplantation still exist. This study aimed to investigate whether pretransplant anti‐A/B antibody removal is mandatory in an ABOi kidney transplant recipient with low baseline isoagglutinin titers.Methods: We adopted a modified desensitization protocol with two doses of rituximab (RTX, 100 mg/body) without pretransplant antibody removal for ABOi kidney transplant recipients with a titer of ≤1:64 (group A; n = 35) and investigated the feasibility of this protocol by comparing it with the clinical outcomes of patients undergoing standard pretransplant plasmapheresis (group B; n = 21).Results: There was no significant difference in the rate of antibody‐mediated rejection within the first month after transplantation between the two groups (11.4% in group A vs. 2% in group B, p = 0.6019). Moreover, no differences were observed in the short‐ and long‐term graft outcomes between the groups. However, two major critical acute antibody‐mediated events occurred in group A; one patient lost the graft due to hyperacute rejection, and the other patient developed thrombotic microangiopathy after surgery. Risk factors predicting these perioperative complications were not identified.Conclusions: We conclude that not only B‐cell depletion using RTX but also pretransplant antibody removal is still recommended even for patients with low isoagglutinin titers. In addition, a new diagnostic tool is needed for accurate risk stratification.

This publication has 24 references indexed in Scilit: